Who buys RPRX stock?
RPRX stock was purchased by a variety of institutional investors in the last quarter, including Marathon Asset Mgmt Ltd, State Street Corp, Geode Capital Management LLC, Swiss National Bank, Northern Trust Corp, abrdn plc, Suvretta Capital Management LLC, and Goldman Sachs Group Inc..
How much of Royalty Pharma's stock is owned by insiders?
In the past three months, Royalty Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,959,226.00 in company stock. 25.86% of the stock of Royalty Pharma is held by insiders.
Is Royalty Pharma efficiently growing its dividend?
Royalty Pharma pays an annual dividend of $0.68 per share and currently has a dividend yield of 1.74%. Royalty Pharma has been increasing its dividend for 2 consecutive year (s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio of Royalty Pharma is 52.71%.
Should I buy or sell Royalty Pharma stock right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 6 buy rating...
What is Royalty Pharma's stock price forecast for 2022?
6 equities research analysts have issued 12 month price objectives for Royalty Pharma's shares. Their forecasts range from $48.00 to $56.00. On ave...
How has Royalty Pharma's stock performed in 2022?
Royalty Pharma's stock was trading at $39.85 at the beginning of the year. Since then, RPRX shares have increased by 1.6% and is now trading at $40...
When is Royalty Pharma's next earnings date?
Royalty Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Roy...
How were Royalty Pharma's earnings last quarter?
Royalty Pharma plc (NASDAQ:RPRX) released its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported $0.61 earnings...
How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?
Royalty Pharma declared a quarterly dividend on Tuesday, April 19th. Shareholders of record on Friday, May 20th will be paid a dividend of $0.19 pe...
Is Royalty Pharma a good dividend stock?
Royalty Pharma(NASDAQ:RPRX) pays an annual dividend of $0.76 per share and currently has a dividend yield of 1.85%. Royalty Pharma has been increas...
Who are Royalty Pharma's key executives?
Royalty Pharma's management team includes the following people: Mr. Pablo Gerardo Legorreta , Founder, Chairman & CEO (Age 57, Pay $49.51M) Mr....
Who are some of Royalty Pharma's key competitors?
Some companies that are related to Royalty Pharma include Johnson & Johnson (JNJ) , Eli Lilly and (LLY) , Pfizer (PFE) , AbbVie (ABBV) , Merck...
When will Royalty Pharma release its earnings?
How much of Royalty Pharma stock is owned by insiders?
Royalty Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021. View our earnings forecast for Royalty Pharma.
How much does Royalty Pharma make?
25.86% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
How much dividend does Royalty Pharma pay?
Royalty Pharma has a market capitalization of $24.48 billion and generates $2.12 billion in revenue each year. The biopharmaceutical company earns $975.04 million in net income (profit) each year or $1.61 on an earnings per share basis.
What is the dividend payout ratio for Royalty Pharma?
Royalty Pharma pays an annual dividend of $0.68 per share and currently has a dividend yield of 1.68% . Royalty Pharma does not yet have a strong track record of dividend growth. The dividend payout ratio of Royalty Pharma is 42.24%. This payout ratio is at a healthy, sustainable level, below 75%.
What is Royalty Pharma?
Based on earnings estimates, Royalty Pharma will have a dividend payout ratio of 21.59% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend. View Royalty Pharma's dividend history.
What is the NASDAQ symbol for Royalty Pharma?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
How to calculate restricted stock?
Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."
Who owns restricted shares of a company?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
How often do exchanges report short interest?
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
How to calculate P/E?
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Is index time real time?
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
How to benefit from a rising market?
Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet
Does Oracle of Omaha sell stock?
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
Royalty Pharma
The Oracle of Omaha keeps selling stock. But these are the exceptions.
About RPRX
Some stock charts might currently not be supported. To try again, please refresh this page.
Premium Research for RPRX
Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies.
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.